Pfizer Lyme vaccine candidate heads to FDA

Ella Jeffries / beckershospitalreview - Pfizer and Valneva’s investigational Lyme disease vaccine candidate, PF-07307405 (LB6V), demonstrated more than 70% efficacy in preventing Lyme disease among individuals age 5 and older, according to topline phase 3 trial results. The prespecified analysi…

AI Summary: Pfizer is advancing a Lyme disease vaccine toward FDA submission despite a messy late‑stage picture: efficacy signals above 70% were reported while a pivotal trial missed its primary endpoint and struggled with low case numbers. Regulators must weigh public health need against statistical nuance as the company pushes for licensure.